NeuroMetrix, a Waltham, MA-based diagnostics and medical device company, announced today that it plans to focus its business around diabetes and the treatment of diabetic neuropathy, a complication of the disease. The company’s website says it developed products for diagnosing and treating peripheral nerve disorders and for providing regional anesthesia and pain control. NeuroMetrix is restructuring and eliminating 27 percent of its staff so that its neurodiagnostic business, which struggled due to changes in reimbursement, will “achieve a positive net cash contribution to the company.”
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
